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MinireviewChemical Genetic Screening
Approaches to Neurobiology
Compound Library Selection
The most widely used probe reagents for chemical ge-
netic studies are small organic molecules, which are
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available from a number of commercial suppliers andCambridge, Massachusetts 02142
include compounds from historical archives, natural
sources, or those produced using combinatorial chem-
istry. Typically, purveyors will supply compounds in 96-
Chemical genetics is an emerging technology for re- or 384-well plates and provide structure data (SD) files
vealing the signaling networks that regulate biological with electronic chemical structures and quality control
phenotypes using exogenous reagents such as small data on each compound’s purity. The major challenge
organic molecules. To study neurobiology using chem- in procuring compounds for chemical genetic screens
ical genetics, high-throughput cell and organismal lies in selecting the small molecules to use. Quantitative
assays can be created to identify compounds and pro- analyses using molecular descriptors can differentiate
teins that regulate diverse neuronal phenotypes, such between various classes of small molecules for the pur-
as cell viability, gene expression level, protein associa- pose of library procurement. For example, polar surface
tion, protein aggregation, glutamate uptake, mem- area is a molecular descriptor that correlates with pene-
brane polarization, mitochondrial function, neurite trability through the blood-brain barrier and is a useful
outgrowth, and growth cone composition. This power- filter when selecting compounds for neurobiological ap-
ful set of tools will enable the molecular dissection plications (Root et al., 2002). For more information on
of complex processes that occur within the nervous the blood-brain barrier and strategies for penetrating it,
system. see the accompanying minireview by Pardridge (2002
[this issue of Neuron]).
Cell and Organismal Model Systems
Introduction for Studying Neurobiology
Chemical genetics is a process that uses exogenous In order to test a large number of compounds within a
ligands to reveal the molecular circuitry controlling bio- reasonable period of time, it is necessary to make use
logical phenotypes (Schreiber, 1998; Stockwell, 2000a, of high-throughput screening (HTS) technology, which
2000b). Analogous to classical forward genetic screens enables the performance of tens of thousands of dis-
in model organisms, this approach makes use of high- crete assays each day. This powerful new tool can be
throughput, phenotypic assays to identify small mole- brought to bear on many cellular and organismal pheno-
cules that disrupt gene product function in a way that types of relevance to neurobiology. Such cell or organis-
alters a phenotype of interest. Although most efforts mal models must be adapted to a plate-based HTS envi-
and definitions of chemical genetics limit the approach ronment. One class of tractable model systems consists
to strategies using small organic compounds, a wider of yeast-based screens, which allows for the perfor-
definition would include other exogenous reagents, mance of many tens of thousands of assays per day
such as small interfering RNAs (Elbashir et al., 2001) but is limited by the facts that yeast cells are less perme-
or peptide aptamers. Once such phenotype-modifying able to many compounds than human cells, that only
10%–20% of human genes have a yeast ortholog, andreagents are identified, they can be used to identify their
that many neuronal processes do not have a counterpartmacromolecular targets, usually DNA, RNA, or protein.
in yeast cells. A second class of model systems consistsUsing this process, it is possible to identify genes and
of non-neuronal mammalian tumor cell lines, which allowproteins that comprise the pathways and networks that
for assays involving protein aggregation and general cellregulate biological systems. In effect, this method
biological functions, such as apoptosis, transcription,allows, for the first time, the use of an unbiased genetic
translation, splicing, protein degradation, and mitochon-approach in diverse mammalian systems, i.e., the chem-
drial function. A third class of model systems consistsical equivalent of saturation mutagenesis. Moreover, it is
of immortalized neuronal cell lines, such as rat PC12possible to use these small molecule probes, identified
cell, which can be induced to differentiate into neuronalthrough the chemical genetic screening process, to re-
cells by treatment with nerve growth factor (Greene andveal the various cellular functions of such genes and
Tischler, 1976), murine N2A neuroblastoma cells, whichproteins once they have been identified. Although little
can be induced to differentiate into neurons using ahas been published on the topic of chemical genetic
variety of methods (Olmsted et al., 1970), ST14A cells,screens related to neurobiology, the field is ripe for dis-
which express a temperature-sensitive variant of thesection using this new set of tools. This review focuses
simian virus 40 large T oncoprotein and can be inducedon the discovery and use of small molecules to explore
to differentiate at 39C (Cattaneo and Conti, 1998), orbasic biological processes, but it is surely the case that
NSC34 cells, which are immortalized cells that constitu-many small molecules discovered in phenotypic screens
tively manifest characteristics of motor neurons (Cash-could be drug candidates, providing another impetus
man et al., 1992). Finally, a fourth class consists of organ-for undertaking a search for such compounds.
ismal model systems, such as worm, fly, zebrafish, and
mouse models, which are obviously less amenable to
high-throughput assays but more accurately reproduce1Correspondence: stockwell@wi.mit.edu
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neurobiological processes. For example, expression of also be a useful phenotypic readout. For example, the
expression level of the excitatory amino acid transportera huntingtin N-terminal fragment containing 128 gluta-
mines in the six touch receptor neurons of Caenorhab- 2 (EAAT2) is altered in astrocytes in the spinal cord of
mice and humans with ALS (Lin et al., 1998). Thus, itditis elegans causes touch insensitivity, forming the ba-
sis for a medium-throughput screening assay (Parker et would be of interest to identify pathways and proteins
that affect EAAT2 expression in order to better under-al., 2001). Expression of mutant -synuclein, TAU, or
ataxin-3 in Drosophila melanogaster causes age-depen- stand its regulation via transcription, translation, splic-
ing, and degradation.dent progressive neurodegeneration, providing models
for Parkinson’s Disease, Alzheimer’s Disease, and Protein aggregation has emerged as a common event
in neurodegenerative diseases such as Creutzfeldt-Spinocerebellar Ataxia type 3, respectively (Muqit and
Feany, 2002). With creative thinking, it should be possi- Jakob Disease (CJD), Alzheimer’s Disease (AD), Hunt-
ington’s Disease (HD), Parkinson’s Disease (PD), andble to convert many existing cellular and organismal
assays into robust, automated screens that can accom- amyotrophic lateral sclerosis (ALS). Assays that report
on protein aggregation are of broad interest for the studymodate the testing of hundreds of thousands of com-
pounds. of these neurodegenerative diseases, as they may shed
light on the connection between protein aggregationPhenotypic Readouts and Assay Technologies
The majority of high-throughput screens utilize an assay and disease pathogenesis. Aggregates can be observed
in diverse systems ranging from yeast cells to humanwhose end product is a spectroscopic change, such as
a change in fluorescence, luminescence, or absorption. brain sections, suggesting they form via conserved, fun-
damental processes. Chemical genetic screens can beA recent trend in high-throughput screening is the devel-
opment of high-content screens that capture more infor- used to shed light on the intracellular pathways that
regulate aggregate formation and clearance. A recentmation per sample, such as microscopy-based screens
that detect changes in the subcellular localization of chemical screen for inhibitors of-synuclein fibril forma-
tion identified numerous dopamine-like catecholaminesproteins or in the morphology of cells.
The presence of live, viable cells is a useful phenotypic that cause accummulation of -synuclein protofibrils
(Conway et al., 2001). This screen revealed that dopa-readout for those cases in which a disease allele causes
cellular toxicity. Viability dyes exist that selectively stain mine can be oxidatively ligated to -synuclein and sug-
gests a possible basis for the dopaminergic selectivitylive cells or dead cells and therefore enable detection
of disease allele-induced toxicity in a high-throughput of -synuclein-associated neurotoxicity in Parkinson’s
Disease.fashion. For example, a mutant allele of the hungtingtin
gene causes cell death in differentiated ST14A neuronal Many neuronal processes can be detected most ef-
fectively using microscopy. Recent developments in au-cells (Rigamonti et al., 2000), and mutants of superoxide
dismutase-1 (SOD1) that cause amyotrophic lateral scle- tomated microscopy have stimulated an interest in high-
content, or imaging-based, screens. In this paradigm,rosis also cause cell death in the presence of oxidative
stress in differentiated N2A cells (Pasinelli et al., 1998). an image is obtained of cells or organisms treated with
each test compound and scored for the relevant pheno-In such cases, it is possible to perform screens for en-
hancers and suppressors of this toxicity to identify those type. Such microscopy-based screens are slower than
conventional platereader-based screens but offer thepathways and processes that functionally interact with
the toxic allele. opportunity to detect more complex phenotypes. For
example, neurite outgrowth of PC12 cells can be usedIn addition, it is possible to make use of viability
assays to perform synthetic lethal screens when a dis- as a phenotypic marker for neurotrophic signaling (Wu
and Bradshaw, 2000). In addition, detection of specificease-causing allele does not directly cause cell death
(Stockwell et al., 1999). In this approach, one searches proteins in the growth cone of a neurite can be used as
the basis for an imaging-based screen. The Survivalfor pathways that, when inhibited or activated, cause
cell death only in the presence or absence of an allele Motor Neuron (SMN) protein has been shown to localize
to growth cone and filopodia-like structures in neuronalof interest. For example, glutamate causes selective tox-
icity in the presence of mutant SOD1, suggesting that cells (Fan and Simard, 2002). Compounds that disrupt
or promote neurite extensions or SMN localization couldglutamate-induced signaling is involved in the mecha-
nism of mutant SOD1-mediated cell death (Roy et al., be used to shed light on the pathways and proteins that
regulate these processes (Figure 1). Although subjective1998). Of course, it is important to determine that such
synthetic lethality does not arise because two weak cell assessment of images obtained in such a high-content
screening mode is possible, a quantitative and auto-death stimuli are simply additive in terms of their gross
toxicity. A counter screen for selectivity relative to other mated method for analzying such images is more reli-
able and allows for greater throughput.weakly lethal stimuli (toxic alleles or small molecules)
must be performed. For example, it would be important Development of High-Throughput Assays
Once a model system and phenotypic readout are se-to determine that glutamate does not cause increased
toxicity in the presence of unrelated toxic proteins (such lected, it is necessary to develop a robust, miniaturized
assay that can be adapted to robotic instrumentation,as mutant huntingtin,  amyloid, etc.) or other weakly
toxic compounds, such as tubulin inhibitors. If such typically in 96-well or 384-well plates. This involves opti-
mizing assay parameters such as number of cells, com-counter screens reveal that glutamate only causes in-
creased toxicity when mutant SOD is present, it is likely position of growth medium and assay buffers, washing
conditions, length of incubation, plate type, and platethat there is a functional connection between glutamate
and mutant SOD. coating method. During the optimization of these assay
parameters, the separation between the positive controlThe expression level of a specific gene product can
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Figure 2. Optimization of the Z Factor during Assay Development
A positive control and a negative control are used to optimize assay
conditions such that the separation between the mean of the posi-
tive signal () and the mean of the negative signal () is maximized.
Simultaneously, the variability of the positive () and negative ()
signal is minimized. The Z factor, which is defined as Z  1  {[3 	
(  )]/(  )}, incorporates all of these parameters and is
used as a quantitative score of assay quality (Zhang et al., 1999).
fying protein targets of small molecules is affinity chro-
matography, which has its origins in the identification
Figure 1. An Example of an Imaging-Based Assay that Could Be of the protein targets of dopamine and acetylcholine in
Adapted for High-Throughput Screening
the 1960s and 1970s. However, newer methods of target
Survival Motor Neuron (SMN) is shown to be localized in the growth identification are being developed that are simpler and
cone of retinoic acid-treated mouse P19 embryonal carcinoma cells.
faster. Protein array profiling and mRNA and phage dis-SMN is stained in green, GAP-43 (a growth cone marker) in red, the
play, for example, are emerging methods used to identifynucleus in blue, and colocalized SMN and GAP-43 in yellow. The
arrowhead indicates a growth cone-like structure (Fan and Simard, specific binding proteins for a small molecule of interest.
2002). Figure reprinted by permission of Oxford University Press (L. Protein arrays consist of proteins deposited in a regular
Fan and L.R. Simard, Human Molecular Genetics 11, 1605–1614). grid, typically on a microscope slide. Such arrays have
been used in proof-of-principle experiments to identify
binding proteins for small molecules (MacBeath and
Schreiber, 2000; Ziauddin and Sabatini, 2001). Messen-signal and negative control signal is maximized, while
signal variability is minimized. A quantitative index that ger RNA display, phage display, and expression cloning
are methods for displaying proteins derived from a cDNAincorporates all of these parameters, known as the Z
factor, has been developed and is widely used in these library to test their interaction with a candidate small
molecule. For example, an expression cloning strategyoptimization studies (Figure 2). Typically, an assay must
have a Z factor greater than 0.2 in order to be sufficiently revealed that the protein target of capsaicin, the active
ingredient in hot chili peppers, is vanilloid receptor sub-robust for high-throughput screening (Zhang et al.,
1999). type 1, a heat-activated ion channel present in sensory
neurons (Caterina et al., 1997).Once the assay is developed, compounds are typically
screened at one concentration, such as 10 M, ideally There are a variety of additional emerging tools for
studying the mechanism of action of a small molecule.in replicate. Active compounds are selected for retesting
in a dose-response series to determine the maximum Cellular profiling methods, including transcription and
proteomic profiling, have been used to view the globalachievable signal and the concentration at which 50% of
this maximum is achieved (EC50). These are quantitative molecular changes induced by a compound in cells or
organisms. In some cases, the pattern of transcriptionalparameters for the activity and potency of each com-
pound in the assay and allow for a relative ranking of or protein-level changes induced by a small molecule
illuminate the mechanism by which the small moleculethe active compounds.
Target Identification and Mechanistic Elucidation acts. In cases where the phenotype of interest is seen
in a model organism, classic genetic screens in yeast,The most potent and most active compounds are stud-
ied in secondary assays that serve to characterize fur- worms, and flies can be used to identify genes that,
when mutated, cause resistance or sensitization to ather the activity profile of the compounds. Ultimately, it
is desirable to identify the molecular bases governing small molecule. Finally, RNA interference can be used
to test the effects of knocking down specific transcriptsthe phenotypic effects of these compounds, ideally by
identifying protein targets and downstream effectors of that are implicated in these experiments. If a target
protein is involved in mediating the effects of a smallactive compounds. There are a variety of methods for
studying the mechanism of action of small molecules, molecule, directly or indirectly, then reducing the con-
centration of the target protein should either cause sen-including affinity chromatography, protein array profiling
(testing the ability of a compound to bind to each mem- sitization or resistance to the compound, depending on
whether the mechanism of action involves a gain ofber of a protein array), mRNA or phage display, tran-
scription profiling, proteomic profiling, classic genetic function or a loss of function. Any one of these methods
may fail for a specific compound, but in aggregate, theyscreens, and RNA interference.
A conventional and well-validated method for identi- represent a powerful arsenal of tools for dissecting the
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Stockwell, B.R., Haggarty, S.J., and Schreiber, S.L. (1999). Chem.molecular pathways that mediate the phenotypic alter-
Biol. 6, 71–83.ations induced by exogenous reagents.
Wu, Y.Y., and Bradshaw, R.A. (2000). J. Biol. Chem. 275, 2147–2156.Conclusion
Zhang, J.-H., Chung, T.D.Y., and Oldenburg, K.R. (1999). J. Biomol.Many areas for innovation remain for chemical genetic
Screen. 4, 67–73.studies of neurobiology. There is a need for better and
Ziauddin, J., and Sabatini, D.M. (2001). Nature 411, 107–110.more diverse cell models of relevance to neurobiology
that are compatible with high-throughput screens. Cell
lines that can be inducibly and rapidly differentiated
from an immortalized cell type represent attractive solu-
tions to this problem. However, in such cases it is critical
to determine which aspects of neuronal function are
recapitulated in the differentiated model system. Detec-
tion of novel phenotypes with relevance to neurobiology
and neurodegeneration also remains a critical issue in
this emerging field. New phenotypic readouts that are
amenable to high-throughput testing will undoubtedly
result in the discovery of interesting new compounds
and targets regulating neurobiological processes. Fi-
nally, faster and better methods of target identification
would be invaluable in accelerating the final stages of
the chemical genetic process, providing valuable new
tools for the dissection of neurological processes.
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